Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs Sells 8,360 Shares

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 8,360 shares of Liquidia stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $14.58, for a total transaction of $121,888.80. Following the completion of the sale, the chief executive officer now directly owns 826,985 shares in the company, valued at approximately $12,057,441.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Roger Jeffs also recently made the following trade(s):

• On Monday, March 18th, Roger Jeffs sold 28,583 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total transaction of $452,183.06.

Liquidia Stock Performance

Shares of Liquidia stock traded up $0.16 on Wednesday, hitting $13.74. 426,187 shares of the company’s stock were exchanged, compared to its average volume of 943,607. The company has a 50-day simple moving average of $14.77 and a 200-day simple moving average of $10.88. The stock has a market capitalization of $1.04 billion, a PE ratio of -11.27 and a beta of 0.16. Liquidia Co. has a 1 year low of $5.71 and a 1 year high of $16.99.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). The business had revenue of $4.53 million for the quarter, compared to analysts’ expectations of $5.29 million. Liquidia had a negative return on equity of 132.16% and a negative net margin of 448.89%. On average, analysts expect that Liquidia Co. will post -1.01 EPS for the current fiscal year.

Institutional Trading of Liquidia

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Liquidia by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 2,843,922 shares of the company’s stock valued at $34,212,000 after acquiring an additional 69,524 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Liquidia in the 4th quarter worth about $849,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Liquidia by 9.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,342 shares of the company’s stock worth $137,000 after buying an additional 989 shares during the last quarter. Bluefin Capital Management LLC bought a new stake in shares of Liquidia in the 4th quarter worth about $302,000. Finally, Barclays PLC increased its holdings in shares of Liquidia by 1,105.2% in the 4th quarter. Barclays PLC now owns 103,021 shares of the company’s stock worth $1,239,000 after buying an additional 94,473 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $28.00 target price on shares of Liquidia in a report on Wednesday, April 10th. Wedbush reissued an “underperform” rating and set a $3.00 target price on shares of Liquidia in a report on Thursday, December 21st. HC Wainwright boosted their target price on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, March 14th. Bank of America upped their price target on shares of Liquidia from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, LADENBURG THALM/SH SH upped their price target on shares of Liquidia from $15.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $21.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).